A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase IIα in vivo

Molecular Pharmacology

Volumn 72, Issue 4, 2007, Pages 1003-1014

  Grauslund, Morten ^a,b   Thougaard, Annemette Vinding ^b   Füchtbauer, Annette ^c   Hofland, Kenneth Francis ^b   Hjorth, Peter Hansen ^c   Jensen, Peter B ^b,d   Sehested, Maxwell ^a,b   Füchtbauer, Ernst Martin ^c   Jensen, Lars H ^a,b,e  

^a Mental Health Services CPH   (Denmark)

^b BioAlliance Pharma   (France)

^c AARHUS UNIVERSITY   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS(3,5 DIOXOPIPERAZIN 1 YL)ETHANE; 2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ANTHRACYCLINE; BIS(DIOXOPIPERAZINE) DERIVATIVE; CISPLATIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; IRON CHELATING AGENT; PIPERAZINEDIONE; RAZOXANE; SERINE; TOPOISOMERASE IIALPHA; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DRUG EXTRAVASATION; EMBRYONIC STEM CELL; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; FEMALE; GENE; GENE LOCUS; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HYDROLYSIS; IN VIVO STUDY; IRON CHELATION; MALE; MEASUREMENT; MOLECULAR INTERACTION; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; RING OPENING; TISSUE INJURY; TISSUE NECROSIS; TOP2A GENE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; MICE; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; PIPERAZINES; RAZOXANE;

EID: 34748893547     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.036970     Document Type: Article

References (40)

1. Akimitsu N, Adachi N, Hirai H, Hossain MS, Hamamoto H, Kobayashi M, Aratani Y, Koyama H, and Sekimizu K (2003) Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha. Genes Cells 8:393-402.
2. Austin CA and Marsh KL (1998) Eukaryotic DNA topoisomerase II beta. Bioessays 20:215-226.
3. Baird CL, Gordon MS, Andrenyak DM, Marecek JF, and Lindsley JE (2001) The ATPase reaction cycle of yeast DNA topoisomerase II. Slow rates of ATP resynthesis and Pi release. J Biol Chem 276:27893-27898.
4. Baird CL, Harkins TT, Morris SK, and Lindsley JE (1999) Topoisomerase II drives DNA transport by hydrolyzing one ATP. Proc Natl Acad Sci U S A 96:13685-13690.
5. Bakowski MT, Prentice HG, Lister TA, Malpas JS, McElwain TJ, and Powles RL (1979) Limited activity of ICRF-159 in advanced acute leukemia. Cancer Treat Rep 63:127-129.
6. Classen S, Olland S, and Berger JM (2003) Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 100:10629-10634.
7. Cvetković RS and Scott LJ (2005) Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65:1005-1024.
8. Falck J, Jensen PB, and Sehested M (1999) Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIα gene. J Biol Chem 274:18753-18758.
9. Hajji N, Pastor N, Mateos S, Dominguez I, and Cortes F (2003) DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193. Mutat Res 530:35-46.
10. Hasinoff BB, Hellmann K, Herman EH, and Ferrans VJ (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28.
11. Hasinoff BB, Kuschak TI, Yalowich JC, and Creighton AM (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50:953-958.
12. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, and Huebner E (2003a) Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol 3:89-99.
13. Hasinoff BB, Schroeder PE, and Patel D (2003b) The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol Pharmacol 64:670-678.
14. Hofland KF, Thougaard AV, Dejligbjerg M, Jensen LH, Kristjansen PE, Rengtved P, Sehested M, and Jensen PB (2005a) Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin Cancer Res 11:6722-6729.
15. Hofland KF, Thougaard AV, Sehested M, and Jensen PB (2005b) Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res 11:3915-3924.
16. Holm B, Sehested M, and Jensen PB (1998) Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 4:1367-1373.
17. Huang KC, Gao H, Yamasaki EF, Grabowski DR, Liu S, Shen LL, Chan KK, Ganapathi R, and Snapka RM (2001) Topoisomerase II poisoning by ICRF-193. J Biol Chem 276:44488-44494.
18. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC, and Andoh T (1995) DNA Topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55:2299-2303.
19. Jensen LH, Nitiss KC, Rose A, Dong J, Zhou J, Hu T, Osheroff N, Jensen PB, Sehested M, and Nitiss JL (2000a) A novel mechanism of cell killing by antitopoisomerase II bisdioxopiperazines. J Biol Chem 275:2137-2146.
20. Jensen LH, Renodon-Cornière A, Wessel I, Langer SW, Sokilde B, Carstensen EV, Sehested M, and Jensen PB (2002) Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 61:1235-1243.
21. Jensen LH, Wessel I, Moller M, Nitiss JL, Sehested M, and Jensen PB (2000b) N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance. FEBS Lett 480:201-207.
22. Kobayashi M, Adachi N, Aratani Y, Kikuchi A, and Koyama H (2001) Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells. Cancer Lett 166:71-77.
23. Langer SW, Sehested M, and Jensen PB (2000) Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 6:3680-3686.
24. Morris SK, Baird CL, and Lindsley JE (2000) Steady-state and rapid kinetic analysis of topoisomerase II trapped as the closed-clamp intermediate by ICRF-193. J Biol Chem 275:2613-2618.
25. Mouridsen H, Langer S, Buter J, Eidtmann H, Rosti G, de WM, Knoblauch P, Rasmussen A, Dahlstrom K, Jensen P, et al. (2007) Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 18:546-550.
26. Oestergaard VH, Knudsen BR, and Andersen AH (2004) Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193. J Biol Chem 279:28100-28105.
27. Ramírez-Solis R, Davis AC, and Bradley A (1993) Gene targeting in embryonic stem cells. Methods Enzymol 225:855-878.
28. Renodon-Cornière A, Jensen LH, Nitiss JL, Jensen PB, and Sehested M (2003) Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance. Biochemistry 42:9749-9754.
29. Roca J, Ishida R, Berger JM, Andoh T, and Wang JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A 91:1781-1785.
30. Roca J and Wang JC (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell 77:609-616.
31. Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, and Jensen PB (1998) Chinese hamster ovary cells resistant to the topoisomerase ii catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 58:1460-1468.
32. Sorensen TK, Grauslund M, Jensen PB, Sehested M, and Jensen LH (2005) Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II. Biochem Biophys Res Commun 334:853-860.
33. Swiatek PJ and Gridley T (1993) Perinatal lethality and defects in hindbrain development in mice homozygous for a targeted mutation of the zinc finger gene Krox20. Genes Dev 7:2071-2084.
34. van Hille B and Hill BT (1998) Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents. Cancer Chemother Pharmacol 42:345-356.
35. Von Hoff DD, Howser D, Lewis BJ, Holcenberg J, Weiss RB, and Young RC (1981) Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 65:249-252.
36. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440.
37. Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, and Sehested M (1999) Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Res 59:3442-3450.
38. Wessel I, Jensen LH, Renodon-Cornière A, Sorensen TK, Nitiss JL, Jensen PB, and Sehested M (2002) Human small cell lung cancer NYH cells resistant to the bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser mutation in the Walker A ATP binding site of topoisomerase II alpha. FEBS Lett 520:161-166.
39. Xiao H, Mao Y, Desai SD, Zhou N, Ting CY, Hwang J, and Liu LF (2003) The topoisomerase IIβ circular clamp arrests transcription and signals a 26S proteasome pathway. Proc Natl Acad Sci U S A 100:3239-3244.
40. Yang X, Li W, Prescott ED, Burden SJ, and Wang JC (2000) DNA topoisomerase IIbeta and neural development. Science 287:131-134.